A trial in COPD patients of the Nrf2 activating molecule sulforaphane improved the reduced phagocytosis of bacteria witnessed in alveolar macrophages from COPD patients [124]. The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.